Grace Therapeutics, Inc GRCE

Healthcare Biotechnology

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

<< Previous

Bullboard Posts

Next >>

(53)
•••

Comment by Canadian_101on Nov 06, 2021 10:12am

279 Views

Post# 34095553

RE:For the record

What a SH_IT Show this has been, thank god I dumped all my shares and moved on before they announced the final results, my spider sense told me something was majorly wrong when they delayed the reults, personally I cannot believe this company is still in business with the same management team in place after the horribly run trials, BUYER BEWARE is all I can say.

Justhalffull wrote: If you had invested $10,000 on Feb 7 2012, you would now have 245.87. If you need any more evidence about this outfit, you should not be investing in stocks.

<< Previous

Bullboard Posts

Next >>

Anaergia signs $25M biomethane deal in Italy